HCM
ARCT icon

Hayman Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Hayman Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-89,399
Closed -$3.78M – 4
2015
Q3 		$3.78M Buy
+89,399
New +$4.7M 1.74% 12

Other funds holding ARCT

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Hayman Capital Management's ARCT Position: Q4 2015 in Review

Hayman Capital Management sold out of Arcturus Therapeutics (ARCT) in Q4 2015, closing a stake of 89,399 shares — an estimated $3.78M sold.

Hayman Capital Management first reported a position in ARCT in Q3 2015 and held it in 1 quarter. The position peaked at $3.78M in Q3 2015. 50 funds tracked by Wall St. Rank hold ARCT as of Q4 2015.

  • Hayman Capital Management reported no remaining Arcturus Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Hayman Capital Management sold 89,399 Arcturus Therapeutics shares in Q4 2015, an estimated $3.78M.
  • Hayman Capital Management first reported a position in Arcturus Therapeutics in Q3 2015 and held it in 1 quarter.
  • Hayman Capital Management's Arcturus Therapeutics position peaked at $3.78M in Q3 2015.
  • 50 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2015.

Based on Hayman Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.